
Opinion|Videos|October 11, 2024
Meningococcal Infection and NMOSD
Author(s)Sean Pittock, MD
Key Takeaways
- Eculizumab and ravulizumab increase meningococcal infection risk, necessitating vaccination in treated patients.
- Phase 3 and long-term studies emphasize the need for vigilant monitoring and prophylactic measures despite vaccination.
Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Discuss the risk of meningococcal infection with eculizumab and ravulizumab in phase 3 and long-term extension studies.
- There may be concerns with meningococcal vaccination and its impact on relapse activity. What is your interpretation of these data?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts New Drug Application for Tau PET Imaging Agent MK-6240 in Alzheimer Disease
2
Apomorphine Sublingual Film Displays Efficacy in Elderly Patients with Parkinson Disease
3
Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited
4
Expanding Patient Expectations When Managing Generalized Myasthenia Gravis: A Treating Physician’s Experience with IMAAVY™ (nipocalimab-aahu)
5






































